Effects of PNPLA3 I148M on hepatic lipid and very-low-density lipoprotein metabolism in humans.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 34411351.
- Also identified by DOI 10.1111/joim.13375.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The phospholipase domain-containing 3 gene (PNPLA3)-148M variant is associated with liver steatosis but its influence on the metabolism of triglyceride-rich lipoproteins remains unclear. Here, we investigated the kinetics of large, triglyceride-rich very-low-density lipoprotein (VLDL), (VLDL<sub>1</sub> ), and smaller VLDL<sub>2</sub> in homozygotes for the PNPLA3-148M variant. The kinetics of apolipoprotein (apo) B100 (apoB100) and triglyceride in VLDL subfractions were analysed in nine subjects homozygous for PNPLA3-148M and nine subjects homozygous for PNPLA3-148I (controls). Liver fat was >3-fold higher in the 148M subjects. Production rates for apoB100 and triglyceride in VLDL<sub>1</sub> did not differ significantly between the two groups. Likewise, production rates for VLDL<sub>2</sub> -apoB100 and -triglyceride, and fractional clearance rates for both apoB100 and triglyceride in VLDL<sub>1</sub> and VLDL<sub>2</sub> , were not significantly different. Despite the higher liver fat content in PNPLA3 148M homozygotes, there was no increase in VLDL production. Equally, VLDL production was maintained at normal levels despite the putative impairment in cytosolic lipid hydrolysis in these subjects.
Medical subject headings
- Acyltransferases
- Lipid Metabolism
- Lipoproteins, VLDL
- Liver
- Phospholipases A2, Calcium-Independent